Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

 Key Statistics

Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co., Inc.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

 Company News
Vertex Pharmaceuticals (MA) (VRTX) To Present At The Barclays Global Healthcare Conference On March 11 3/7/2014 6:46:44 AM    More...
From Startup To Billion-Dollar Biotech: An Inside Look At Vertex Pharmaceuticals (MA) (VRTX) 2/28/2014 7:52:14 AM    More...
FDA Approves Vertex Pharmaceuticals (MA) (VRTX)'s KALYDECO™ (Ivacaftor) For Use In Eight Additional Mutations That Cause Cystic Fibrosis 2/24/2014 6:56:55 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) To Present At The RBC Global Healthcare Conference On February 25 2/21/2014 7:26:24 AM    More...
Governor Patrick And The Massachusetts Life Sciences Center Celebrate The Opening Of The New Vertex Pharmaceuticals (MA) (VRTX) Facility In Boston 2/4/2014 11:57:08 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Reports Full-Year And Fourth Quarter 2013 Financial Results And Provides Financial Guidance For 2014 1/30/2014 8:48:20 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Announces Sustained Viral Response Rate (SVR4) Data From All-Oral Study Of VX-135 In Combination With Daclatasvir In Hepatitis C 1/9/2014 10:20:02 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Announces Upcoming Presentation At J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2013 Financial Results 1/8/2014 7:47:58 AM    More...
Vertex Pharmaceuticals (MA) (VRTX)'s Cystic Fibrosis Drug Ivacaftor Misses Goal In Late-Stage Study But Helps Some Adults 12/19/2013 6:42:37 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Unloads INCIVO® Product Royalty Rights For $152 Million 11/20/2013 6:41:35 AM    More...